Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11
- Drug Discovery
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 369410
Licensor shall be hereby deemed to have granted and hereby grants to Licensee the exclusive right and license, even as to Licensor and its Affiliates, except for the limited purpose of conducting Research and Development activities with respect to Back-up Compounds or formulations in the Territory, with the right to grant sublicenses, right, title and interest in and to the Exclusively Licensed lP to make, have made, use, sell, offer for sale and import Compounds under such Licensor Program as and into Licensee Products in the Field during the Term.
For the Technology Transfer after Option Exercise, Licensor shall deliver to Licensee, all Information and material in its possession and Control relating to the Compounds, in such Licensee Development Program, and any other such Information as may be in Licensors Control and in the possession of any subcontractors appointed by Licensor.
This strategic alliance is to discover, develop and commercialize novel inhibitors of endosomal Toll-like Receptors (TLRs) for the treatment of immuno-inflammatory diseases. TLRs are key receptors of the innate immune system that can induce strong inflammatory responses.
Compound means each compound comprising an oligonucleotide-based immunoregulatory sequence (IRS) that inhibits IC50 < 200nM in a cellular assay.
The Field means any use or purpose, including without limitation, the treatment, palliation, prevention and/or diagnosis of any human or animal disease, disorder or condition, whether as a prescription pharmaceutical product or over-the-counter medicine or otherwise.
This agreement will carry out up to three different research and development programs to discover and develop oligonucleotides as inhibitors of certain toll-like receptors or combinations thereof.
IPSCIO Record ID: 299249
Licensor grants, commencing at the expiration of the Research Term and for a period of six years thereafter, a non-exclusive, world-wide right and license under the Licensor Patents and Licensor Know-How, and Licensors rights in the Joint Patents and Joint Know-How, solely to discover, synthesize, and, in connection with Licensees activities under this Agreement, make and use Active Compounds for use in the Field.
For the Commercialization License to Licensee, Licensor grants an exclusive, world-wide right and license under the Licensor Patents, the Licensor Know-How and under Licensors rights in the Joint Know-How and Joint Patents, solely to [conduct development on, and to make, have made and use for such purpose, Back-Up Compounds and Collaboration Compounds for use in the Field and to make, have made, import, use, sell and offer for sale Licensed. Products) for use in the Field.
For the Cross-License of Know-How Licensor grants a non-exclusive license under the Licensor Know-How for any purpose or use.
Licensed Product means any product, including any formulation thereof, containing or comprising a Collaboration Compound.
Active Compound means any compound that
— has the ability to inhibit (or, in the case of a prodrug, an active species of which inhibits) cathepsin S with a [K; equal to or less than 100 nM];
— has greater than [100- fold selectivity] for cathepsin S against an [appropriate panel of cathepsins in appropriate assays,] as determined by the JRC; and
— has appropriate [in-cell activity in concentrations of less than IO ÂµMin a relevant cell based assay(s)] selected by the JRC.
Cathepsin S is associated with certain inflammatory diseases, such as arthritis, asthma, atherosclerosis and a variety of autoimmune diseases.
Cysteine proteases are enzymes that are responsible for the cleavage and breakdown of other natural proteins in normal biological processes. In disease conditions, cystein proteases can often be misregulated, providing an entry point for drug intervention. Cathepsin S has been associated with the processing and activation of the antigen receptor called MHC-II, essential for the initiation of both normal and pathological immune responses mediated by T-cells. Drugs designed to inhibit this enzyme may provide a novel method for control of antigen-induced response in multiple inflammatory and autoimmune disease states, the companies believe.
IPSCIO Record ID: 367570
For the Options, Licensor grants the exclusive right, exercisable at Licensees sole discretion, to elect to include any or all of the following as Licensee Development Compounds
– With respect to Project 1 the Candidate Selection Compound or PoC Compound, as applicable, from Project 1 that triggered Licensees right to exercise its Candidate Selection Option or PoC Option, as applicable, all Back-Up Compounds and Follow-On Compounds with respect thereto, and all other Collaboration Compounds under development in Project 1 that are Hits;
– With respect to each TPP Subprogram in Project 2, the PoC Compound from such Target Product Profile or TPP Subprogram in Project 2 that triggered Licensees right to exercise its PoC Option, all Back-Up Compounds with respect thereto, and all other Collaboration Compounds included within such TPP Subprogram in Project 2 that have at a minimum achieved the Lead Declaration Criteria, as confirmed by the JRC;
– With respect to Project 3, the PoC Compound that triggered Licensees right to exercise its PoC Option, all Back-Up Compounds with respect thereto, and all other Collaboration Compounds included in Project 3 that have at a minimum achieved the Lead Declaration Criteria, as confirmed by the JRC; and
– With respect to each TPP Subprogram in Project 4, the PoC Compound that triggered Licensees right to exercise its PoC Option, all Back-Up Compounds with respect thereto, and all other Collaboration Compounds included within such TPP Subprogram in Project 4 that have at a minimum achieved the Lead Declaration Criteria, as confirmed by the JRC.
For the Research Collaboration, Licensor grants a non-exclusive license under the Licensor IP, solely as and to the extent necessary or important to conduct activities for which Licensee is responsible under the Research Plans during the Research Collaboration Term.
For the Development and Commercialization, Licensor grants the exclusive right and license in the Territory, with the right to grant sublicenses, under the Licensor IP to make, have made, use, sell, offer for sale and import the Licensee Collaboration Compounds as and into Products in the Field during the Term.
Target means any of the following the hepatitis C virus protease; LeuRS; P-lactamase; or the Designated Target, which target shall be selected from the following two targets transpeptidase and signal peptidase.
Licensor Compound means a boron-containing small molecule compound Controlled by Licensor or a Licensor Affiliate.
LeuRS means bacterial leucyl tRNA synthetase.
PoC Compound means a Collaboration Compound resulting from PoC Trials.
The Field means any use or purpose, including the treatment, palliation, and/or prevention of any human or animal disease, disorder or condition; provided, however, that the Field shall specifically exclude the treatment, palliation, and/or prevention of onychomycosis.
Onychomycosis is a fungal infection of the nails that causes discoloration, thickening, and separation from the nail bed.
IPSCIO Record ID: 203240
For commercialization, Licensor grants to the Licensee of England, the exclusive, right and license in the Territory, with the right to grant sublicenses, under all of Licensors rights, title and interest in and to the Licensors Technology, to make, have made, use, sell, offer for sale and import the Progressed Compounds which are the subject of each of such Product Options as and into Product Candidates and as and into Licensed Products in the Field during the Term of this Agreement.
For Trademarks for licensed Products, Licensor shall assign its rights and title to such trademark(s) to Licensee, upon request.
Licensor grants the exclusive right, exercisable at Licensees sole discretion, to elect to obtain exclusive worldwide rights to continue to develop and commercialize at least four (4) and no more than six (6) Option Compounds (and their associated Back-up Compounds), as Product Candidates and into Licensed Products.
The patents include Sulfonamides, Piperazines and derivatives for inflammation and immunes.
Traficet-EN is intended to control the inflammatory response underlying inflammatory bowel disease, or IBD, by targeting the chemokine receptor known as CCR9. In adults, CCR9 is found primarily on a population of T cells, a subset of the bodyâ€™s inflammatory cells, that migrate selectively to the digestive tract.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of RA patients contains high levels of activated CCR1 chemokine ligands. Blocking CCR1 is intended to reduce inflammation and prevent subsequent joint destruction by suppressing the infiltration of inflammatory cells into the arthritic joint.
Traficet-EN (CCX282 or GSKâ€™786) â€” Our most advanced drug candidate, currently in three pivotal Phase III clinical trials being conducted by our partner for the treatment of patients with moderate-to-severe Crohnâ€™s disease.
Field shall mean any use or purpose, including without limitation the treatment, palliation, and/or prevention of any human or animal disease, disorder or condition; provided, however, that the Field shall specifically exclude the commercialization of protein therapeutics directed against Collaboration Targets.
IPSCIO Record ID: 253935
For the technology Transfer by Licensor, Licensor grants to Licensee the exclusive, even as to Licensor and its Affiliates, license, non-transferable, with the right to sublicense, under the Licensor Patents and Licensor Know-How, to make, have made, use, sell, offer to sell, export, import and otherwise exploit or Commercialize Licensed Products that are the subject of the Option so exercised, during the Term, and throughout the Field and the Territory.
5-HT4 Partial Agonist Program means EPIXs program to develop a partial agonist to the 5-HT4 receptor.
Licensor Program means a program of drug design, discovery and Development activities to be conducted by Licensor hereunder against Program Targets. The first Licensor Program is the 5-HT4 Partial Agonist Program.
The patents are for Thienopyridinone Compounds and Methods of Treatment.
GPCRs are the largest known class of molecular targets with proven therapeutic value. Of the top 50 selling drug worldwide, as identified by IMS, it is estimated that nearly 40 percent interact with GPCRs as their target proteins. GPCRs convert signals received from outside the cell into biological processes inside the cell.
The strategic collaboration agreement is to discover, develop and market novel medicines targeting four G-protein coupled receptors (GPCRs) for the treatment of a variety of diseases, including EPIXâ€™s novel 5-HT4 partial agonist program, PRX-03140, in early-stage clinical development for the treatment of Alzheimerâ€™s disease.
IPSCIO Record ID: 344537
This agreement includes a non-exclusive grant back to Licensor.
Compounds means compounds that were or are identified, synthesized, discovered, designed or acquired by or on behalf of (A) Licensor or its Affiliates either prior to the date hereof or during the Term, (B) Licensee or its Affiliates during the term of the Research and Development Program, or (C) a Non-ND Partner or its Affiliates either prior to the date hereof or during the Term, but only if during the term of a Non-ND Research Program; either are HDAC Inhibitors or (b) are developed pursuant to the Collaboration (subject to the last sentence of this defined term Compound); possess certain basic drug characteristics and range of chemotypes with pan and sub-type selective HDAC inhibition characteristics, as mutually agreed to by the Parties from time to time; and are used or useful in the Field.
HDAC means HDAC Class I and HDAC Class II, collectively.
HDAC Inhibitors means Small Molecules that directly inhibit HDAC Class I or HDAC Class II enzymatic activity or which have therapeutic effect through the inhibition of HDAC Class I or HDAC Class II enzymes.
Licensor Program Compounds means the approximately(Â± 5%) 1014 Compounds.
Field means the treatment or prevention of Huntingtons disease, Parkinsons disease, Alzheimers disease, and the Other Neurodegenerative Diseases using an HDAC Inhibitor or any Compound developed pursuant to the Collaboration; provided, however, that the term Field shall cease to include ALS or Dementia if, as to a particular Subject Indication.
'Applicable Field' means the Field, but only as to the disease indications within the Research and Development Program that is the subject of a Back-Out (i.e., the AD R&D Program, the HD R&D Program or the PD R&D Program), in each case including any of the Other Neurodegenerative Diseases.
IPSCIO Record ID: 352729
Upon â€™s Licensees exercise of the Option, Licensor grants a worldwide, irrevocable, exclusive license, with the right to sublicense, under the Licensors Patents, Know-How and interest in the Joint Inventions and Joint Patents, to make, have made, use, sell, offer for sale and/or import Licensed Compounds and Products comprising Licensed Compounds in the Field in the Territory, and a worldwide, irrevocable, non-exclusive license, with the right to sublicense, under the Licensor Technical Information to make, have made, use, sell, offer for sale and/or import Licensed Compounds and Products comprising Licensed Compounds in the Field in the Territory, collectively the License.
License Grant Upon Expiration of the Royalty Term. SGI hereby grants to GSK a worldwide, non-exclusive fully paid-up license, with the right to sublicense, under the SGI Know-How and SGI Technical Information to continue to make, have made, use, sell, offer for sale and/or import Licensed Compounds and Products comprising Licensed Compounds in the Field in the Territory upon Expiration in Entirety.
CLIMBâ„¢ or CLIMB means that certain proprietary process, comprising hardware, software, bench chemistry, synthesis, analysis and testing used by Licensor for the purpose of the discovery, evaluation and development of new chemical entities.
Compound means any inhibitor of DNA methyltransferases, including DNA methyltransferase 1 (DNMTÂ·1) and/or DNA methyltransferase 3 (DNMT-3) owned or Controlled by SGI, as well as any pro-drugs of such compounds, any metabolites of such compounds having DNMT target activity, all stereoisomers of such compounds including salts, and any solvates or polymorphs of such compounds. Compound will not include Decitabine (S-aza-2 – deoxycytidine) and all stereoisomers, salts, polymorphs, esters and acids of Decitabine, Vidaza'â€¢, or analogues of azacitidine. Compound will also not include polynucleosides or polynucleotides comprising at least one base of cytidine or its derivatives or analogues, including Decitabine.
Epigenetics refers to the regulation of genes with mechanisms other than changes to the underlying DNA sequence. Epigenetic processes are widely believed to play a central role in the development and progression of almost all cancers.
IPSCIO Record ID: 299264
Licensee will utilize Licensor Technology for its drug discovery activities under Licensee know-how concerning the identification and characterization of novel small molecule inhibitors.
In addition to Licensees non-exclusive right to use Licensor Technology as necessary to conduct activities under the Research Program, Licensor grants an exclusive, worldwide license, with the right to sublicense to use such Licensor Technology as is necessary to make, have made, use, have used, sell, have sold, import and export Active Compounds, Development Compounds and/or Products in the Territory.
Initial target is Type 3 Phosphodiesterases.
Alternative targets are DNA Polynucleotide kinase (DNA-PK), Poly (ADP-ribase) polymerase (PARP), and, Modulators of the interaction between the G-beta subunit of the G-protein and beta-adrenergic receptor kinase (gB-BARK)
IPSCIO Record ID: 314349
Licensor hereby grants to Licensee a nonexclusive, perpetual worldwide license to make, have made, import, use, and/or develop any Program Invention(s), for which one or more employees of Licensor is/are the only Inventor(s) of such Program Invention and for which Licensee has a nonexclusive license, a nonexclusive right and license, during the Research Term, to practice any Program Invention and/or Joint Program Invention assigned to Licensor.
Licensor hereby grants to Licensee a perpetual, worldwide right and license under Licensor Intellectual Property, as applied specifically and solely to Licensee Compounds and/or Licensor Leads, with the right to grant sublicenses, to make, have made, modify, import, use, promote, offer to sell and sell Licensee Compounds and/or Licensor Leads for any purpose.
Licensee Compound shall mean any synthetic chemical compound or biological material, which compound or material
A. is represented in compound libraries/collections owned or controlled by Licensee and/or Licensee Affiliate (where Affiliate' is defined hereinbelow) as of the Effective Date, whether or not the same compound or material is represented in compound libraries/collections owned or controlled by Licensor and/or Licensor Affiliate as of the Effective Date; or
B. is acquired by or prepared by Licensee independently of the Research Program; or
C. is acquired or prepared by Licensee under the Research Program, including any analog of any Licensor Compound (as defined hereinbelow) prepared by Licensee, but excluding any Licensor Compound prepared by Licensee; or
D. is discovered or identified by or for Licensee based on criteria developed under the Research Program.
Licensor Compound shall mean any synthetic chemical compound or biological material that has demonstrated antifungal activity according to Licensors translation inhibition screening assays, which
A. is either owned by or licensed, with permission to sublicense, to Licensor as of the Effective Date, including but not limited to a compound or material provided to Licensee by Licensor under the provisions of the Material Transfer Agreement between Licensor and Licensee effective June 7, 1995; or
B. is in-licensed by, with the right to sublicense, or acquired by Licensor during the Research Term and which does not correspond to an Licensee Compound within Licensees or an Licensee Affiliates libraries/collections prior to the date of acquisition by Licensor; or
C. is any salt, ester, amide, complex, chelate, hydrate, isomer, stereoisomer, crystalline or amorphous form, prodrug, metabolite, metabolic precursor, or analog of any of the above included compounds or materials.
Program Inventions shall mean all inventions, innovations, improvements, ideas, discoveries, technology, know-how, methods, applications and products (whether or not patentable) arising under the Research Program, which are conceived, derived, reduced to practice, made or developed during the term of and the four (4) months following conclusion of the Research Program by one or more individuals who are employees of one of the parties at the time of the inventive contribution of such individual(s).
Joint Program Inventions shall mean all inventions, innovations, improvements, ideas, discoveries, technology, know-how, methods, applications and products (whether or not patentable) arising under the Research Program, which are conceived, derived, reduced to practice, made or developed during the term of and the four (4) months following the conclusion of the Program by at least two individuals, at least one individual of which is an employee, at the time of the inventive contribution of such individual, of one of the parties hereto, and at least one individual of which is an employee, at the time of the inventive contribution of such individual, of the other party hereto.
Licensor Lead shall mean a Licensor Compound which (a) in the judgment of the JMT under the Research Program, demonstrates selective fungal translation inhibition according to Licensors mycotic in vitro translation assays and mammalian in vitro translation assays; and (b) demonstrates an MIC equal to or less than 25ug/ml v. Candida albicans CCH 442, or such other Candida strain(s) agreed upon by the JMT; and (c) has a chemical structure amenable to modification through medicinal or combinatorial chemistry, as judged by the JMT. A compound or material shall cease to be a Licensor Lead if, after three (3) twelve (12) – month periods following the termination or expiration of the Research Term, Licensee has not Identified such compound or material to Licensor as among the up to ten (10) Licensor Leads that Licensee has selected as being those to which Licensee desires to retain exclusive rights, to the extent that Licensor can grant such exclusive rights.
Licensor is a drug discovery company focused on the identification of novel leads and the development of potential drug candidates for the treatment of infectious diseases.
IPSCIO Record ID: 298928
Licensor grants, during the Research Term, an exclusive, non-transferable license to use the Program Assays to screen the Program Substances in accordance with the Research Program and a nontransferable, non-exclusive license under the Licensor-owned Program Patents and the Licensor Technology other than the Program Assays to the extent necessary to screen the Program Substances against the Program Assays in accordance with the terms of the Research Program.
For the Preliminary Development by Licensee of Option-Compounds, Licensor grants to an exclusive license under the Licensor-owned and jointly owned Program Patents, the Licensor-owned and jointly owned Program Know-How and the LicensorTechnology for the limited purpose of conducting biological studies, medicinal chemistry, pharmacological development, preliminary animal safety studies or other pre-IND development activities with respect to any Option Compound within any Option Program.
Program Product shall mean any pharmaceutical product which results during the Research Term from research conducted with respect to a Program Compound. Each Program Product shall be deemed to include all indications, formulations, line extensions or modes of administration thereof.
Option Compound shall mean a Program Substance which as a result of screening activities under the Research Program, reveals Anti-Viral Activity in only one or more Option Targets, which is not designated by Licensee as a Restricted Compound and as to which Licensor has commenced and is proceeding with preliminary development activities within two (2) years after the expiration of the Research Term.
— Option Product shall mean any pharmaceutical product which results during the Research Term or within two (2) years thereafter, from research conducted with respect to an Option Compound. Each Option Product shall be deemed to include all indications, formulations, line extensions or modes of administration thereof.
— Option Program shall mean either the Herpes Simplex Virus Option Program or the Cytomegalovirus Option Program, as the case may be.
The Targets and Assays are
â€¢ Human Immunodeficiency Virus Integrase
â€¢ Human Immunodeficiency Virus Tat
â€¢ Hepatitis C Virus Helicase
The Core Target Assays are
â€¢ Human Immunodeficiency Virus Integrase
â€¢ Human Immunodeficiency Virus Tat
â€¢ Hepatitis C Virus Helicase
The Option Targets are
â€¢ Cytomegalovirus E2
â€¢ Herpes Simplex Virus HelicasePrimase
The Option Target Assays are
â€¢ Recombinant Cytomegalovirus
â€¢ Cytomegalovirus E2
â€¢ Recombinant Herpes Simplex Virus
â€¢ Herpes Simplex Virus HelicasePrimase
IPSCIO Record ID: 344539
For the Development and Commercialization License, Licensor grants an exclusive, even as to Licensor, right and license, under the Licensor Intellectual Property, to Develop Selected Compounds into Licensed Products intended for use in the Field in the Territory, and make and have made, use, offer for sale, sell, have sold and import Selected Compounds and Licensed Products in the Field in the Territory.
For the Grant of Certain Jointly Developed Methyl Gene Collaboration Intellectual Property for use Outside the Field, Licensor grants a perpetual, irrevocable, non-exclusive right and license to use, solely outside the Field, Licensor Collaboration Intellectual Property that is Formulation Technology or Know-How that directly relates to the physicochemical property pharmacokinetics/pharmacodynamics relationship in ocular tissue, and is jointly developed, conceived or created by or on behalf of Licensor and/or its Affiliates, on the one hand, and by or on behalf of Licensee and/or its Affiliates, on the other hand.
Inhibitors of VEOF Receptor and HOF Receptor;
Inhibitors of Protein Tyrosine Kinase Activity;
Kinase Inhibitors and Uses Thereof;
Processes and Intermediates for Preparing Fused;
Heterocyclic Kinase Inhibitors;
Inhibitors of Protein Tyrosine Kinase Activity;
Inhibitors of Kinase Activity.
A Compound is a molecule that is a small molecule that is a small molecule tyrosine kinase inhibitor as its main mechanism of action, and any salts, hydrates, solvates, polymorphs, free base, isomers, prodrugs, metabolites and/or liposomal or other formulations thereof or other compositions consisting of such molecule non-covalently bonded with other moieties, but excluding any derivative of such molecule in which the chemical structure of such molecule is altered.